Do you want to read an article? Please log in or register.
Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
United European Gastroenterol J.
Guidi L, Pugliese D, Tonucci TP, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A
doi: 10.1177/2050640619873784.
COMMENTED
Gastrointestinal DiseasesInflammatory Bowel Disease
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
Clin Gastroenterol Hepatol.
Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN
doi: 10.1016/j.cgh.2020.07.012.
Inflammatory Bowel Disease
Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months
Clin Gastroenterol Hepatol.
Williet N, Boschetti G, Fovet M, Di Bernado T, Claudez P, Del Tedesco E, Jarlot C, Rinaldi L, Berger A, Phelip JM, Flourie B, Nancey S, Paul S, Roblin X
doi: 10.1016/j.cgh.2016.11.023.
Inflammatory Bowel Disease
Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases
J Crohns Colitis.
Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F
doi: 10.1093/ecco-jcc/jjaa035.
Inflammatory Bowel Disease
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases
Eur J Clin Invest.
Carbone F, Bodini G, Brunacci M, Bonaventura A, Vecchiè A, Liberale L, Crespi M, Baldissarro I, Dallegri F, Savarino V, Montecucco F, Giannini EG
doi: 10.1111/eci.13002.
Inflammatory Bowel Disease
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission
J Gastroenterol Hepatol.
Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A
doi: 10.1111/jgh.14751.
Inflammatory Bowel Disease
Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab
doi: 10.1097/MEG.
Inflammatory Bowel Disease
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice
Biologicals.
Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T
doi: 10.1016/j.biologicals.
Inflammatory Bowel Disease
High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease
Inflamm Bowel Dis.
Barnes EL, Long MD, Kappelman MD, Martin CF, Sandler RS
doi: 10.1093/ibd/izy378.